Adiponectin and the cardiovascular system: from risk to disease

Review

DOI: 10.1007/s11739-007-0027-9

Cite this article as:
Tarquini, R., Lazzeri, C., Laffi, G. et al. Int Emergency Med (2007) 2: 165. doi:10.1007/s11739-007-0027-9

Abstract

Adiponectin is known to play a role in fatty acid and glucose metabolism through a change in insulin sensitivity and activation of fuel oxidation by AMP-activated protein kinase. Adiponectin can be considered an important factor able to modulate the adipovascular axis which, through genomic and environmental influences, affects the cardiovascular risk milieu, from the pre-metabolic syndrome — through the metabolic syndrome — to the overt atherosclerotic process and its clinical manifestations. Hypoadiponectinaemia can be viewed as an early sign of a complex cardiovascular risk factor predisposing to the atherosclerosis process as well as a contributing factor accelerating the progress of the atherosclerotic plaque. In addition, adiponectin per se holds a protective role thanks to its anti-inflammatory and antiatherogenic properties. The early identification of patients “at cardiovascular risk” means in the current practice to search for indexes of metabolic derangements and pro-inflammatory status (adiponectin) from adolescence and childhood.

Keywords

Adiponectin Metabolic syndrome Visceral fat Cardiovascular risk Adipokynes 

Copyright information

© Springer-Verlag Italia Srl 2007

Authors and Affiliations

  • R. Tarquini
    • 1
    • 3
  • C. Lazzeri
    • 2
  • G. Laffi
    • 1
  • G. F. Gensini
    • 2
  1. 1.Internal Medicine Department Azienda Ospedaliero-Universitaria CareggiUniversity of FlorenceFlorenceItaly
  2. 2.Heart and Vessel Department Azienda Ospedaliero-Universitaria CareggiUniversity of FlorenceFlorenceItaly
  3. 3.Internal Medicine Department Azienda Ospedaliero-Universitaria CareggiUniversity of FlorenceFlorenceItaly

Personalised recommendations